Quantcast
Last updated on April 21, 2014 at 4:58 EDT

Latest Oncolytics Biotech Stories

2014-04-14 12:33:05

CALGARY, April 14, 2014 /PRNewswire/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC) (NASDAQ:ONCY) today announced that Dr. Adel Jebar of the Leeds Institute of Cancer and Pathology, University of Leeds, presented a poster at the 8(th) Annual International Conference on Oncolytic Virus Therapeutics held in Oxford, UK. The poster, titled "Combined anti-viral and anti-tumour therapy for virus-associated liver cancer," covered preclinical research into the treatment of hepatocellular...

2014-04-14 12:33:03

CALGARY, April 14, 2014 /PRNewswire/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC) (NASDAQ:ONCY) today announced that a poster authored by Bolton, et al was presented at the 8(th) Annual International Conference on Oncolytic Virus Therapeutics held in Oxford, UK. The poster, titled "Resistance to oncolytic reovirus is associated with high expression of Yes-Associated Protein (YAP-1) in head and neck cancer," covered preclinical research focused on identifying biomarkers...

2014-04-11 08:24:10

CALGARY, April 11, 2014 /PRNewswire/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC) (NASDAQ:ONCY) today announced that Dr. Alan Melcher, Professor of Clinical Oncology and Biotherapy at the University of Leeds, presented at the 8(th) Annual International Conference on Oncolytic Virus Therapeutics held in Oxford, UK. Dr. Melcher's presentation, titled "Clinical Virotherapy and Immune Modulation; Bench to Bedside and Back Again," covered early clinical research showing that...

2014-04-08 08:30:08

CALGARY, April 8, 2014 /PRNewswire/ - Oncolytics Biotech Inc. (TSX:ONC) (NASDAQ:ONCY) ("Oncolytics" or the "Company") today announced additional data from the Company's randomized, double-blinded clinical study examining REOLYSIN(®) in combination with carboplatin and paclitaxel in patients with second-line, platinum-refractory, taxane-naïve head and neck cancers (REO 018). The REO 018 study enrolled a total of 167 patients. Patients on the control arm were treated with carboplatin,...

2014-04-07 08:29:25

CALGARY, April 7, 2014 /PRNewswire/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC) (NASDAQ:ONCY) today announced that research collaborators will make two poster presentations at the American Association for Cancer Research 2014 Annual Meeting. The Meeting is being held from April 6(th) to 9(th), 2014 in San Diego, CA. "The data presented by these collaborators is contributing to our evolving understanding of how REOLSYIN(®) works, what biomarkers may be predictive of improved...

2014-03-13 08:28:11

CALGARY, March 13, 2014 /PRNewswire/ - Oncolytics Biotech Inc. (TSX:ONC, NASDAQ:ONCY) ("Oncolytics" or the "Company") today announced its financial results and operational highlights for the year ended December 31, 2014. "In 2013, we reported data from a number of clinical studies, which included our first data correlating specific biomarkers with survival in NSCLC lung cancer patients and culminated with the reporting of our first randomized data in head and neck cancer," said...

2014-03-04 16:25:40

CALGARY, March 4, 2014 /PRNewswire/ - Dr. Brad Thompson, President and CEO of Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY), will participate in the 34(th) Annual Cowen and Company Healthcare Conference in a session on Wednesday March 5(th), 2014 at 8:40 a.m. ET. The conference takes place from March 3(rd) to 5(th) at the Boston Marriott Copley Place in Boston, MA. A live audio link to the webcast session will be available at: http://wsw.com/webcast/cowen16/ONCY or on the...

2014-02-27 08:30:40

CALGARY, Feb. 27, 2014 /PRNewswire/ - Oncolytics Biotech Inc. ("Oncolytics" or the "Company") (TSX:ONC; NASDAQ:ONCY) announced today that it has entered into a share purchase agreement (the "Purchase Agreement") with Lincoln Park Capital Fund, LLC ("LPC") that will provide an initial investment in Oncolytics of US$1.0 million and make available additional periodic investments of up to US$25.0 million over a 30-month term (the "Financing"). Upon execution of the Purchase...

2014-02-25 08:30:56

CALGARY, Feb. 25, 2014 /PRNewswire/ - Dr. Brad Thompson, President and CEO of Oncolytics Biotech Inc. (TSX: ONC) (NASDAQ: ONCY), will participate in the 2014 RBC Capital Markets Global Healthcare Conference in a session on Wednesday February 26(th), 2014 at 8:30 a.m. ET. The conference will take place on February 25(th) and 26(th) in New York, NY at the New York Palace Hotel. A live audio link to the webcast session will be available at:...

2013-12-03 08:31:37

CALGARY, Dec. 3, 2013 /PRNewswire/ - Dr. Brad Thompson, President and CEO of Oncolytics Biotech Inc. (TSX: ONC) (NASDAQ: ONCY), will present a corporate overview of the Company at the 25(th) Annual Piper Jaffray Healthcare Conference on Wednesday December 4(th), 2013 at 8:00 a.m. ET. The conference will take place on December 3(rd) and 4(th) in New York, NY at the New York Palace. A live audio link to the Piper Jaffray webcast presentation will be available at:...